{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:51:39Z","timestamp":1772754699218,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020274","name":"EUSA Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jtct.2022.05.029","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:44:03Z","timestamp":1653162243000},"page":"487.e1-487.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Pashna N.","family":"Munshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-8037","authenticated-orcid":false,"given":"Kwang W.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Zurko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C. Villaboas","family":"Bisneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamad A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-8745","authenticated-orcid":false,"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.05.029_bib0001","series-title":"Cancer Facts & Figures 2022","year":"2022"},{"key":"10.1016\/j.jtct.2022.05.029_bib0002","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.05.029_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0004","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0005","first-page":"981","article-title":"High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party","volume":"14","author":"Sweetenham","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0006","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.05.029_bib0007","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/bmt.2010.289","article-title":"Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over","volume":"46","author":"Andorsky","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0008","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","article-title":"Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity","volume":"87","author":"Elstrom","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0009","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0010","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.32752","article-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","volume":"126","author":"Jagadeesh","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.05.029_bib0011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jtct.2022.05.029_bib0012","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0013","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0014","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7574","article-title":"Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5","volume":"39","author":"Hamadani","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0016","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0017","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0018","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.05.029_bib0019","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2010.02.010","article-title":"Difficulties in decision making regarding chemotherapy for older cancer patients: a census of cancer physicians","volume":"78","author":"Wan-Chow-Wah","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0021","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.3390\/cancers12123553","article-title":"Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance","volume":"12","author":"Berendsen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2022.05.029_bib0022","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","article-title":"Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.05.029_bib0023","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.029_bib0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oncolo\/oyab004","article-title":"Translating the biology of diffuse large B-cell lymphoma into treatment","volume":"27","author":"Danilov","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2022.05.029_bib0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.6004\/jnccn.2014.0010","article-title":"Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic","volume":"12","author":"Wildes","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jtct.2022.05.029_bib0026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/asheducation-2016.1.99","article-title":"Biologic vs physiologic age in the transplant candidate","volume":"2016","author":"Artz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2022.05.029_bib0027","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.05.029_bib0028","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2019.09.007","article-title":"Evaluation of the impact of autologous hematopoietic stem cell transplantation on the quality of life of older patients with lymphoma","volume":"26","author":"Lemieux","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0029","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1634\/theoncologist.2017-0499","article-title":"Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis","volume":"23","author":"Sun","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2022.05.029_bib0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","article-title":"Autologous hematopoietic stem cell transplantation in elderly patients (>\/= 70 years) with non-Hodgkin's lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study","volume":"6","author":"Hermet","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0031","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (>or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.05.029_bib0032","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2008.09.008","article-title":"Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR)","volume":"14","author":"Lazarus","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bjh.13561","article-title":"Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma","volume":"171","author":"Gohil","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0034","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbmt.2020.09.013","article-title":"Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age","volume":"26","author":"Flannelly","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.029_bib0035","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database","volume":"60","author":"Shaw","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.05.029_bib0036","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.1997.15.7.2644","article-title":"Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors","volume":"15","author":"Mitchell","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0037","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1002\/cam4.4249","article-title":"Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States","volume":"10","author":"Vaughn","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.05.029_bib0038","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/cncr.33831","article-title":"Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.05.029_bib0039","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.05.029_bib0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/annonc\/mdw653","article-title":"Treatment outcomes for older patients with relapsed\/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial","volume":"28","author":"Davison","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.05.029_bib0042","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.jtct.2022.05.029_bib0043","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.05.029_bib0044","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.05.029_bib0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:37Z","timestamp":1763003257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722013203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2666636722013203"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}